Trial Profile
High Dose Interleukin-2 (IL-2) Therapy In 'Lymphodepleted Primed' Patients With Metastatic Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Sargramostim (Primary) ; Mesna
- Indications Malignant melanoma
- Focus Therapeutic Use
- 25 Oct 2011 Actual end date (March 2010) added as reported by ClinicalTrials.gov.
- 25 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Feb 2008 Status change from recruiting to in progress.